• Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
  • Log In
    • Register
Contacts us @ MediPr.org
Medical News Asia | Powered by ['mediPr]
  • Home
  • HER2 Explorer
    • By Tumor Type
    • Breast Cancer
    • Gastric Cancer
    • Lung Cancer
    • Pantumor
    • By Alterations
    • Amplification
    • Overexpression
    • Mutation
  • TROP Tool
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Tag Archive for: her2-Breast Cancer

Navigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker Assessment

31 July 2025/in HER2 Explorer, Breast Cancer 2nd Homepage/by Stijn van den Borne, MSc

Due to the availability of human epidermal growth factor receptor 2 (HER2)-directed therapies, testing for HER2 alterations, including overexpression, gene amplification or mutations is recommended in treatment guidelines for various tumor types, including breast cancer, gastric cancer, biliary tract cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.1-10

Read more
https://www.medi-paper.com/wp-content/uploads/2025/05/5th-website-content-banner_Thumbnail-scaled.png 1367 2560 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2025-07-31 15:56:482025-07-31 16:26:32Navigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker Assessment

Decoding HER2 IHC Scoring Guidelines: Understanding Immunohistochemistry Scoring in Different Cancers

3 March 2025/in HER2 Explorer 2nd Homepage/by Stijn van den Borne, MSc

Human Epidermal Growth Factor Receptor 2 (HER2) aberrations, such as overexpression, HER2 gene amplification, and HER2 mutations, have been extensively researched and are associated with tumor proliferation in various solid tumor types including breast cancer, gastric cancer, gastroesophageal junction (GEJ) cancer, biliary tract cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and bladder cancer.1 The presence of HER2 aberrations is linked to reduced survival, increased chance of brain metastasis, and treatment resistance.2

Read more
https://www.medi-paper.com/wp-content/uploads/2025/03/3rd-website-content-banner-01-Thumbnail-scaled.png 1367 2560 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2025-03-03 12:11:002025-05-28 15:18:17Decoding HER2 IHC Scoring Guidelines: Understanding Immunohistochemistry Scoring in Different Cancers
Redefining-HERness-HER2-low-and-ultralow-breast-cancers

Redefining HERness: HER2-low and ultralow breast cancers

26 August 2024/in HER2 Explorer 2nd Homepage/by Jessica LAU

The 2018 guidelines from the American Society of Clinical Oncology (ASCO) and the College of American Pathology (CAP) classify human epidermal growth factor receptor-2 (HER2) status in breast cancer (BC) according to immunohistochemistry (IHC) staining results of biopsy specimens, ranging from IHC 0 to IHC 3+, plus in situ hybridization (ISH) test results.1

Read more
https://www.medi-paper.com/wp-content/uploads/2024/08/Redefining-HERness-HER2-low-and-ultralow-breast-cancers_082024-scaled.jpg 1367 2560 Jessica LAU https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Jessica LAU2024-08-26 15:25:182025-05-28 15:04:00Redefining HERness: HER2-low and ultralow breast cancers
HER2 as a biomarker in cancers_0824

HER2 as a biomarker in cancers

16 July 2024/in HER2 Explorer 2nd Homepage/by Jessica LAU

Human epidermal growth factor receptor-2 (HER2) is a member of the erythroblastic oncogene B (ERBB) family of transmembrane tyrosine kinase receptors that also includes epidermal growth factor receptor (EGFR, also known as HER1), and human epidermal growth factor receptors -3 and -4 (HER3, HER4).1,2 Despite being a receptor, HER2 has no known ligand, but its conformation is similar to the ligand-activated form of other ERBB family members, favoring heterodimerization with them.1,3

Read more
https://www.medi-paper.com/wp-content/uploads/2024/07/HER2-as-a-biomarker-in-cancers_0824-scaled.jpg 1367 2560 Jessica LAU https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Jessica LAU2024-07-16 00:09:302025-05-29 15:16:01HER2 as a biomarker in cancers

Categories

Categories

Newsletter


 [‘mediPr] | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | CORTiX AI for Medical Science | Dub-Dub Subtitle Generation
© 2016-2026 MediPaper Medical Communications Ltd. | Website by [’mediPr] Sydney | Singapore | Hong Kong | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
Scroll to top Scroll to top Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings×

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

5
Accept settingsHide notification only